Showing results (151-160 of 247) with videos related to
Sort By:
Pageof 25
American Journal of Clinical Oncology|March 11, 2026
Adjuvant Chemotherapy After Curative Intent Resection of Ampullary Cancer (ADAPTA): Study Protocol for a Pan-European Prospective Multicenter Double Single Arm TrialBas A Uijterwijk, Daniel H L Lemmers, Dorine S Klei, et al.Cancers|June 26, 2026
Cancer-Related Cognitive Impairment in Breast Cancer: Current State of Knowledge, Mechanisms, Diagnosis, Prevention and TreatmentFederica Andreis, Chiara Deori, Valentina Giubileo, et al.The Oncologist|January 8, 2011
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximabMario Scartozzi, Alessandra Mandolesi, Riccardo Giampieri, et al.BMC Cancer|August 29, 2009
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysisMario Scartozzi, Italo Bearzi, Alessandra Mandolesi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2025
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal CancerFilippo Pietrantonio, Lisa Salvatore, Taito Esaki, et al.JAMA Network Open|March 29, 2021
Association of Obesity With Survival Outcomes in Patients With Cancer: A Systematic Review and Meta-analysisFausto Petrelli, Alessio Cortellini, Alice Indini, et al.International Journal of Cancer|January 26, 2010
Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecanMario Scartozzi, Alessandra Mandolesi, Riccardo Giampieri, et al.The Lancet. Oncology|December 14, 2007
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trialStefano Cascinu, Rossana Berardi, Roberto Labianca, et al.The Lancet. Oncology|August 14, 2025
Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trialDominik Paul Modest, Marwan Fakih, Lisa Salvatore, et al.Analytical and Quantitative Cytology and Histology|August 12, 2010
Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an "old" therapeutic targetMario Scartozzi, Italo Bearzi, Alessandra Mandolesi, et al.Pageof 25